Hyperprolactinemia and Fertility: How Elevated Prolactin Affects Conception in India

Prolactin is a hormone produced primarily by the lactotroph cells of the anterior pituitary gland, located at the base of the brain. Its best-known role is stimulating breast milk production after childbirth. However, prolactin has over 300 known functions in the body, including roles in immune regulation, metabolism, and -- critically -- reproductive function.

Under normal circumstances, prolactin levels are kept in check by dopamine, a neurotransmitter released by the hypothalamus. Dopamine acts as the primary inhibitor of prolactin secretion. When this inhibitory mechanism is disrupted, prolactin levels rise above normal.

Hyperprolactinemia is defined as a serum prolactin level above the upper limit of normal:

• Normal range (women): 2-29 ng/mL (varies slightly between laboratories)
• Normal range (men): 2-18 ng/mL
• Mild elevation: 25-50 ng/mL
• Moderate elevation: 50-100 ng/mL
• Severe elevation: >100 ng/mL (often associated with prolactinomas)
• Very high levels: >200 ng/mL (strongly suggestive of macroprolactinoma)

Even mildly elevated prolactin levels can interfere with reproductive function. The degree of elevation often correlates with the severity of menstrual disruption and the likelihood of a specific underlying cause.

Prolactinoma (Pituitary Adenoma)

The most common pathological cause of hyperprolactinemia is a prolactinoma -- a benign (non-cancerous) tumour of the pituitary gland that produces excess prolactin. Prolactinomas account for approximately 40% of all pituitary adenomas and are the single most common cause of persistent, significant hyperprolactinemia.

They are classified by size:

• Microprolactinoma (<10 mm): More common in women, prolactin usually 50-200 ng/mL. These rarely grow and respond excellently to medication.
• Macroprolactinoma (>10 mm): More common in men (partly because men are diagnosed later). Prolactin levels often >200 ng/mL and sometimes exceed 1,000 ng/mL. Can cause headaches and visual field defects due to compression of the optic chiasm.

Prolactinomas are not cancerous. They are slow-growing, and malignant transformation is exceedingly rare. The vast majority shrink significantly with medical treatment.

Medications

Drug-induced hyperprolactinemia is the second most common cause and should always be considered. Medications that block dopamine receptors or deplete dopamine will raise prolactin. Common culprits include:

• Antipsychotics: Risperidone, haloperidol, olanzapine, chlorpromazine (most potent cause)
• Antiemetics: Metoclopramide (Reglan), domperidone
• Antidepressants: SSRIs (fluoxetine, sertraline) -- usually cause mild elevation
• Antihypertensives: Verapamil, methyldopa
• Opioids: Morphine, methadone
• Gastrointestinal agents: Cimetidine, ranitidine (less common)

Drug-induced hyperprolactinemia typically resolves when the offending medication is stopped. Prolactin levels usually normalise within 72 hours to 2 weeks of discontinuation.

Hypothyroidism

Primary hypothyroidism (underactive thyroid) is an important and correctable cause of hyperprolactinemia. When thyroid hormone levels fall, the hypothalamus releases more thyrotropin-releasing hormone (TRH). TRH stimulates not only TSH production but also prolactin release from the pituitary. This creates a compounding hormonal disruption: hypothyroidism impairs fertility directly, and the secondary hyperprolactinemia makes it worse.

Treating the underlying hypothyroidism with levothyroxine normalises both TSH and prolactin levels -- no separate prolactin-lowering medication is needed.

Polycystic Ovary Syndrome (PCOS)

Approximately 15-30% of women with PCOS have mildly elevated prolactin levels. The mechanism is not fully understood but may relate to increased estrogen stimulation of the pituitary or altered dopamine regulation. Prolactin levels in PCOS-associated hyperprolactinemia are usually mildly elevated (25-40 ng/mL).

Idiopathic Hyperprolactinemia

When no identifiable cause is found after thorough evaluation -- no prolactinoma on MRI, no offending medications, normal thyroid function -- the condition is termed idiopathic hyperprolactinemia. This accounts for approximately 30% of cases. It may be caused by very small prolactinomas below MRI detection threshold, subtle alterations in dopamine regulation, or other unidentified factors. Idiopathic hyperprolactinemia responds well to dopamine agonist therapy.

Macroprolactinemia

This is an important laboratory consideration, not a true disease. Macroprolactin is a larger, biologically inactive form of prolactin that is bound to immunoglobulin G (IgG). Some laboratory assays detect macroprolactin, leading to falsely elevated total prolactin readings. Macroprolactinemia accounts for 10-25% of all elevated prolactin results.

Women with macroprolactinemia typically have normal menstrual cycles and normal fertility. If total prolactin is elevated but the patient is asymptomatic and has regular periods, macroprolactin screening should be performed to avoid unnecessary treatment.

Other Causes

Less common causes include:

• Non-functioning pituitary adenomas: Large tumours that compress the pituitary stalk, interrupting dopamine delivery (stalk effect). Prolactin usually <100 ng/mL.
• Chest wall irritation: Herpes zoster, breast surgery, nipple piercing -- via neural reflex arcs
• Chronic renal failure: Impaired prolactin clearance
• Cirrhosis: Altered estrogen metabolism
• Seizures: Transient post-ictal prolactin elevation
• Stress and exercise: Mild, transient elevations

The Central Mechanism: GnRH Suppression

The primary way hyperprolactinemia impairs fertility is by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus. GnRH is the master reproductive hormone that triggers the pituitary to release FSH (follicle-stimulating hormone) and LH (luteinising hormone), which in turn drive ovulation in women and testosterone/sperm production in men.

The chain of disruption works as follows:

1. Elevated prolactin acts on the hypothalamus
2. GnRH pulsatility is suppressed -- both the frequency and amplitude of GnRH pulses are reduced
3. FSH and LH secretion decreases as a result
4. In women: follicular development fails and ovulation does not occur (anovulation)
5. In men: testosterone production falls and spermatogenesis is impaired

This mechanism is called hypogonadotropic hypogonadism -- the reproductive organs are not being adequately stimulated because the pituitary signals have been turned down by excess prolactin.

Effects on Female Fertility

Anovulation and Menstrual Disruption

This is the most direct and common effect. Depending on the severity of prolactin elevation:

• Mild elevation (25-50 ng/mL): May cause luteal phase defects (short, inadequate second half of the cycle) and irregular cycles. Ovulation may still occur sporadically.
• Moderate elevation (50-100 ng/mL): Often causes oligomenorrhea (infrequent periods) and inconsistent ovulation.
• Severe elevation (>100 ng/mL): Typically causes amenorrhea (complete absence of periods) and complete anovulation.

Luteal Phase Defect

Even when ovulation does occur in the setting of mildly elevated prolactin, the quality of the luteal phase may be compromised. Progesterone production by the corpus luteum is insufficient, leading to an endometrium that is inadequately prepared for implantation. This can cause very early pregnancy loss or failure of implantation.

Direct Endometrial Effects

Emerging research suggests that prolactin may have direct effects on the endometrium, independent of its effects on ovulation. Prolactin receptors are present in endometrial tissue, and elevated levels may alter endometrial receptivity and implantation potential.

Effects on Male Fertility

Hyperprolactinemia in men is less commonly diagnosed but can be profoundly impactful:

• Reduced testosterone: Prolactin suppresses GnRH, leading to decreased LH and consequently decreased testicular testosterone production. Testosterone levels may fall to hypogonadal ranges.
• Impaired spermatogenesis: Low testosterone and direct effects of prolactin on the testes reduce sperm production. Sperm count, motility, and morphology may all be affected.
• Erectile dysfunction: This is often the presenting complaint in men. The combination of low testosterone and direct neurological effects of hyperprolactinemia impairs erectile function.
• Decreased libido: Often the earliest symptom in men, preceding erectile difficulties.

Symptoms in Women

• Irregular menstrual cycles (oligomenorrhea): Cycles longer than 35 days or unpredictable timing
• Absent periods (amenorrhea): Complete cessation of menstruation -- the most common presenting symptom
• Galactorrhea: Spontaneous or expressible milky nipple discharge, present in approximately 30-80% of women with hyperprolactinemia. Not dangerous but can be distressing.
• Infertility: Often the reason women seek evaluation, caused by anovulation
• Headaches: May indicate a pituitary adenoma, particularly if persistent and frontal/bitemporal
• Visual disturbances: Bitemporal hemianopia (loss of peripheral vision on both sides) suggests a macroprolactinoma compressing the optic chiasm. This is a red flag requiring urgent evaluation.
• Decreased libido: Less commonly reported in women but can occur
• Vaginal dryness: Due to secondary estrogen deficiency from prolonged hyperprolactinemia
• Bone loss (osteopenia/osteoporosis): Long-standing hyperprolactinemia causes estrogen deficiency, which accelerates bone loss

Symptoms in Men

• Erectile dysfunction: Often the first symptom noticed
• Decreased libido: Gradual reduction in sexual desire
• Gynecomastia: Breast tissue enlargement, present in approximately 10-20% of men with hyperprolactinemia
• Galactorrhea: Rare in men but can occur with very high prolactin levels
• Infertility: Due to low sperm count and quality
• Fatigue and decreased energy: Related to low testosterone
• Headaches and visual changes: If prolactinoma is present; men more commonly present with macroprolactinomas because symptoms develop more insidiously

Step 1: Serum Prolactin Level

A single fasting morning blood sample is the first-line test. Prolactin has a circadian rhythm (highest during sleep, lowest in late morning) and can be temporarily elevated by stress, nipple stimulation, exercise, or a recent meal. To ensure accuracy:

• Draw blood mid-morning (9-11 AM), fasting
• Avoid breast examination or nipple stimulation before the test
• Avoid vigorous exercise that morning
• If the result is mildly elevated (25-50 ng/mL), repeat the test on a different day to confirm

Interpreting prolactin levels:

Step 2: Rule Out Secondary Causes

Before imaging, secondary causes must be excluded:

• Thyroid function tests (TSH, free T4): Primary hypothyroidism causes secondary hyperprolactinemia. If TSH is elevated, treat the thyroid first -- prolactin may normalise without specific treatment.
• Medication review: A thorough review of all medications, including over-the-counter drugs and supplements.
• Pregnancy test: Pregnancy is a normal physiological cause of elevated prolactin and must be excluded.
• Renal and liver function: Chronic kidney disease and liver cirrhosis can elevate prolactin.
• Macroprolactin assay: If prolactin is elevated but symptoms are absent or mild, request macroprolactin testing. This involves PEG (polyethylene glycol) precipitation to remove macroprolactin.

Step 3: Pituitary MRI

If prolactin is persistently elevated after excluding secondary causes, an MRI of the pituitary gland with gadolinium contrast is the standard imaging investigation. MRI can detect:

• Microprolactinomas (<10 mm): Often visible as a small hypointense area within the pituitary
• Macroprolactinomas (>10 mm): Clearly visible, with assessment of optic chiasm compression and cavernous sinus invasion
• Non-functioning pituitary adenomas: Large tumours causing stalk compression
• Empty sella syndrome and other pituitary abnormalities

Not all patients with mild hyperprolactinemia require MRI. Indian clinical practice generally recommends MRI when:

• Prolactin >50 ng/mL (or in some centres, >40 ng/mL)
• Symptoms suggest a mass effect (headaches, visual changes)
• No secondary cause is identified
• Hyperprolactinemia persists after addressing secondary causes

Step 4: Visual Field Testing

Formal visual field testing (perimetry) is recommended when a macroprolactinoma is detected on MRI, particularly if it approaches or contacts the optic chiasm. Bitemporal hemianopia is the classic visual field defect. This is more relevant in men, who more frequently present with macroprolactinomas.

Additional Tests

• Other pituitary hormones: If a pituitary adenoma is found, testing for growth hormone, cortisol (ACTH), and other pituitary hormones ensures the tumour is not co-secreting or causing deficiency of other hormones.
• Bone density (DEXA scan): Recommended for women with long-standing amenorrhea due to hyperprolactinemia, as estrogen deficiency increases osteoporosis risk.

Standard Diagnostic Tests in India

• Serum Prolactin — First-line test — fasting morning sample. Levels >25 ng/mL in women suggest hyperprolactinemia
• Thyroid Function (TSH, Free T4) — Rules out hypothyroidism as a secondary cause of elevated prolactin
• Macroprolactin Assay (PEG Precipitation) — Distinguishes biologically inactive macroprolactin from true hyperprolactinemia — avoids unnecessary treatment
• Pituitary MRI with Gadolinium — Gold standard imaging to detect prolactinomas (micro or macro) and other pituitary abnormalities
• Visual Field Testing (Perimetry) — Required for macroprolactinomas to assess optic chiasm compression and guide treatment urgency

First-Line: Dopamine Agonists

Dopamine agonist medications are the first-line treatment for hyperprolactinemia, regardless of whether it is caused by a prolactinoma or is idiopathic. These drugs mimic the action of dopamine, the natural inhibitor of prolactin secretion. They are remarkably effective:

• Normalise prolactin in 80-90% of patients
• Restore ovulation in >80% of women
• Shrink prolactinomas by 50-90% in most cases
• Reverse galactorrhea in the majority of patients

Two dopamine agonists are available in India:

Cabergoline (Dostinex)

The preferred dopamine agonist due to its superior efficacy, better tolerability, and convenient dosing.

• Dose: 0.25-0.5 mg twice weekly (starting dose), titrated up to 1-2 mg/week based on prolactin response
• Administration: Oral, taken with food to reduce nausea. Bedtime administration further reduces side effects.
• Advantages: Higher efficacy (normalises prolactin in >90% of microprolactinomas), fewer side effects, twice-weekly dosing improves adherence
• Cost in India: Rs. 150-400 per tablet (0.5 mg); monthly cost approximately Rs. 600-1,600 depending on dose
• Side effects: Nausea, headache, dizziness, fatigue (usually mild and transient). At high doses used in Parkinson's disease, cardiac valve fibrosis has been reported, but this is not a concern at the low doses used for hyperprolactinemia.

Bromocriptine (Parlodel)

The older, established dopamine agonist. Less expensive but less well-tolerated.

• Dose: 1.25-2.5 mg daily (starting), titrated to 5-7.5 mg/day in divided doses
• Administration: Oral, taken with food. Often started at a very low dose (1.25 mg at bedtime) and gradually increased.
• Advantages: Longest safety track record in pregnancy, lower cost
• Cost in India: Rs. 20-80 per tablet (2.5 mg); monthly cost approximately Rs. 60-250
• Side effects: Nausea, vomiting, orthostatic hypotension (dizziness on standing), nasal congestion, constipation. Side effects are more frequent and sometimes limit use.

Treatment Response and Monitoring

After starting dopamine agonist therapy:

• Prolactin levels: Recheck at 4-6 weeks. A significant drop (often >50% reduction) is expected.
• Menstrual cycles: Periods typically resume within 2-3 months of prolactin normalisation. Ovulation may recover even before prolactin fully normalises.
• Tumour size: For prolactinomas, repeat MRI at 6-12 months to assess shrinkage. Most microprolactinomas shrink significantly; macroprolactinomas may show dramatic reduction (50-90%).
• Dose titration: The dose is adjusted to the minimum effective level -- the lowest dose that maintains normal prolactin and regular menstrual cycles.

Surgical Treatment

Surgery is not first-line for most prolactinomas but is indicated in specific situations:

• Resistance or intolerance to dopamine agonists: Approximately 10-15% of prolactinomas (particularly macroprolactinomas) do not respond adequately to medical therapy
• Acute visual compromise: Rapidly progressive visual loss from a large prolactinoma may require urgent surgical decompression
• Patient preference: Some patients prefer definitive surgical treatment over long-term medication
• CSF leak: Rare complication of tumour shrinkage with medication

The surgery is transsphenoidal (through the nose/sinuses) -- minimally invasive and performed by neurosurgeons experienced in pituitary surgery.

• Success rates: 70-90% for microprolactinomas, 30-40% for macroprolactinomas
• Recurrence: 10-50% depending on tumour size and surgical completeness
• Costs in India: Rs. 1.5-4 lakh at major centres, depending on hospital type and city

Other Treatment Options

• Radiation therapy: Reserved for aggressive or malignant prolactinomas refractory to both medication and surgery. Rarely needed.
• Combination therapy: Medication + surgery for large tumours with incomplete surgical response.

This is where hyperprolactinemia truly stands out among causes of infertility: treatment outcomes are excellent.

Ovulation Restoration

• >80% of women with hyperprolactinemia-related anovulation resume regular ovulation with dopamine agonist therapy
• Ovulation typically resumes within 2-3 months of prolactin normalisation
• Conception rates: 80-85% of women who desire pregnancy achieve it after prolactin normalisation, most within 12 months

Natural Conception

The majority of women with hyperprolactinemia do not need IVF. Once prolactin is normalised:

• Regular ovulation resumes
• The menstrual cycle normalises
• Luteal phase function improves
• Natural conception becomes possible

For women under 35 with no other fertility factors, simply normalising prolactin is often sufficient. No additional fertility treatment (IUI, IVF) is needed.

When Additional Fertility Treatment Is Needed

Some women may need further intervention if:

• Other fertility factors co-exist (tubal disease, endometriosis, male factor)
• Ovulation does not resume despite prolactin normalisation (rare -- investigate for other causes)
• Age is a factor: Women over 35-37 may wish to proceed with IUI or IVF more quickly to optimise time
• PCOS co-exists: Ovulation induction with letrozole or clomiphene may be added

Male Fertility Recovery

In men treated with dopamine agonists:

• Testosterone levels normalise in the majority of patients
• Semen parameters improve over 3-6 months
• Libido and erectile function recover
• Natural conception becomes possible once semen parameters improve

Dopamine Agonist Management

Once pregnancy is confirmed, the standard practice for most women with microprolactinomas or idiopathic hyperprolactinemia is to stop the dopamine agonist medication. The rationale:

• The pituitary naturally enlarges during pregnancy (up to 2-3 times normal size) due to estrogen-driven lactotroph hyperplasia
• Microprolactinomas rarely cause clinically significant enlargement during pregnancy (<3% risk of symptomatic growth)
• Bromocriptine has extensive pregnancy safety data showing no increase in birth defects, miscarriage, or adverse fetal outcomes
• Cabergoline data is more limited but reassuring -- no significant increase in birth defects has been documented

Macroprolactinomas During Pregnancy

Women with macroprolactinomas require closer monitoring because the risk of clinically significant tumour growth during pregnancy is higher (approximately 20-30%):

• Pre-pregnancy shrinkage: Ideally, the tumour should be maximally shrunk with medication before conception
• Continue medication: Some specialists recommend continuing the dopamine agonist (particularly bromocriptine) throughout pregnancy for large macroprolactinomas
• MRI monitoring: Not routinely performed in pregnancy (no radiation risk, but gadolinium is avoided). MRI without contrast may be done if symptoms suggest tumour growth.
• Symptom monitoring: New headaches or visual changes during pregnancy should prompt immediate evaluation
• Visual field testing: Performed each trimester for women with macroprolactinomas

Prolactin Monitoring During Pregnancy

Prolactin levels are not routinely monitored during pregnancy because:

• Prolactin naturally rises dramatically during pregnancy (up to 10-20 times normal)
• Elevated prolactin in pregnancy is physiological and expected
• Monitoring levels provides no useful clinical information for managing the tumour
• Clinical symptoms (headaches, visual changes) are more reliable indicators of tumour growth

Breastfeeding

Women with microprolactinomas and idiopathic hyperprolactinemia can breastfeed safely. Dopamine agonists are withheld during breastfeeding because they suppress lactation. After weaning, prolactin levels and tumour status are reassessed, and medication is restarted if needed. Notably, pregnancy and breastfeeding sometimes result in long-term remission of hyperprolactinemia -- up to 30% of women with microprolactinomas do not need medication after pregnancy.

One of the most favourable aspects of hyperprolactinemia treatment is its affordability, particularly in the Indian context.

Diagnostic Costs

• Serum prolactin test: Rs. 300-700
• Thyroid function tests (TSH, fT4): Rs. 200-500
• Macroprolactin assay: Rs. 500-1,200 (not available at all labs)
• Comprehensive hormonal panel (prolactin, TSH, LH, FSH, estradiol): Rs. 1,500-3,000
• Pituitary MRI with contrast: Rs. 5,000-12,000 (varies significantly by city and hospital)
• Visual field testing: Rs. 500-1,500

Treatment Costs (Medical)

• Cabergoline (Dostinex/generic): Rs. 600-1,600 per month
• Bromocriptine (Parlodel/generic): Rs. 60-250 per month
• Follow-up prolactin tests (quarterly once stable): Rs. 300-700 per test
• Annual pituitary MRI (if prolactinoma): Rs. 5,000-12,000

Treatment Costs (Surgical, if needed)

• Transsphenoidal surgery: Rs. 1.5-4 lakh (varies by hospital tier and city)
• Post-operative monitoring: Rs. 5,000-15,000

Cost Comparison

For context, the total first-year cost of treating hyperprolactinemia medically -- including diagnosis, medication, and monitoring -- typically ranges from Rs. 10,000-25,000. This is a fraction of the cost of a single IVF cycle (Rs. 1.5-3.5 lakh). For many women, correcting hyperprolactinemia eliminates the need for expensive assisted reproduction entirely.

While most women with hyperprolactinemia do not need IVF, some situations may require it:

• Co-existing fertility factors (tubal disease, severe male factor, advanced age)
• Persistent anovulation despite prolactin normalisation (rare)
• Failed natural conception after adequate trial (6-12 months)

Pre-IVF Optimisation

Before starting an IVF cycle, prolactin should be normalised and stable on medication. Elevated prolactin during IVF can:

• Impair follicular development
• Reduce oocyte quality
• Decrease implantation rates
• Increase miscarriage risk

Most IVF centres continue dopamine agonist therapy during the IVF cycle and into early pregnancy.

IVF Outcomes

When prolactin is well-controlled, IVF outcomes for women with hyperprolactinemia are generally comparable to the general IVF population. Hyperprolactinemia per se does not reduce egg quality or embryo potential once prolactin levels are normalised.